8.	RELATED PARTY TRANSACTIONS

For the year ended December 31, 2017, the Company paid approximately $16 thousand in consulting fee to a director of the Company. For the nine months ended December 31, 2016, the Company paid $0.1 million in consulting fees to certain directors of the Company.

During April 2016, the Company entered into a consulting agreement with Montel Media, Inc. (“Montel Media”), pursuant to which Montel Media provides consulting services for the promotion of the Company’s clinical trials and ongoing media and marketing strategies. Under the agreement, Montel Media receives $15 thousand per month. For the year ended December 31, 2017 and the nine months ended December 31, 2016, the Company paid Montel Media $0.2 million and $0.1 million, respectively, pursuant to the consulting agreement. Montel Media is owned by Montel Williams, who beneficially owns greater than 5% of the Company’s common stock.

For the year ended December 31, 2017 and nine months ended December 31, 2016, an expense of $0.4 million and $0.2 million, respectively, was included in the change in fair value of derivative financial instruments as the fair value of stock-based compensation attributed to the options granted to a director for consulting services rendered with respect to the design and development of the PoNS device.

The Company’s Chief Medical Officer is a founding member of Clinvue LLC, a company that provides regulatory advisory services for the Company. During the year ended December 31, 2017, the Company paid Clinvue LLC approximately $0.1 million for consulting services. For the nine months ended December 31, 2016, the Company made no payment to Clinvue LLC.

In connection with the December 2017 private placement, the Company’s Chief Executive Officer, its Chief Financial Officer/Chief Operating Officer, two directors and A&B, a greater than 5% owner of the Company’s shares outstanding subscribed in the private placement. The following table summarizes their participation (subscription amount in thousands):

	Units Purchased		Subscription Amount
A&B (HK) Company Ltd.		204,081	$	2,000
Director 1		76,530		750
Director 2		51,019		500
CEO		25,510		250
CFO/COO		15,816		155
		372,956	$	3,655